MDGL: MASH Pool Assumptions Versus Gross To Net Execution Will Shape Outlook

The analyst price target for Madrigal Pharmaceuticals has risen from $529 to $550. Analysts point to survey work that highlights a large MASH treatment pool and higher projected Rezdiffra use, along with updated assumptions for patient mix, revenue growth, margins, and P/E multiples.

Analyst Commentary

Recent research updates around Madrigal Pharmaceuticals show a mix of optimism about the potential MASH treatment pool and a more guarded stance on execution, profitability, and valuation. While some firms have raised price targets on the back of survey work and Rezdiffra adoption assumptions, others are trimming expectations as they reassess key inputs such as gross to net dynamics and peak patient volumes.

One recent report highlighted a higher projected number of MASH patients treated with Rezdiffra in the US, with estimates moving to 193,000 patients from 158,000 previously. That shift reflects confidence in eligible patient numbers and possible treatment uptake. At the same time, there are opposing views where analysts are easing back price targets and forecasts after reviewing more recent financial commentary and model inputs.

On the more constructive side, some analysts point to survey work that supports a large potential treatment population and robust Rezdiffra use assumptions. These reports argue that, if those treatment estimates prove realistic, Rezdiffra could be a central revenue driver for Madrigal over time. However, the range of price targets and the presence of both upward and downward revisions underline that there is still disagreement among analysts about how these assumptions should feed into long term earnings power and valuation.

A key area of focus in recent commentary has been gross to net adjustments. One major firm explicitly cited comments from Madrigal's team on these adjustments when lowering its price target to US$529 from US$570 and maintaining a Neutral stance. For readers, this highlights that even within a broadly positive clinical and regulatory story, smaller changes to reimbursement, discounts, and access terms can influence modeled revenue and margin outcomes.

Overall, the current analyst backdrop suggests that the story around Madrigal is still developing. Some research points to a sizeable MASH market and meaningful Rezdiffra penetration, while bearish analysts are concentrating on execution questions, profitability visibility, and how much future growth is already reflected in the stock's valuation multiples.

Bearish Takeaways

Bearish analysts who recently lowered their price targets are signaling concern that previous forecasts may have been too optimistic relative to updated commentary on gross to net adjustments and revenue conversion.
The Neutral rating maintained alongside a lower US$529 price target suggests some hesitation around near to medium term earnings visibility, even as the underlying MASH opportunity remains large.
Price target trims by bearish analysts point to worries that current valuation may already discount a strong uptake path for Rezdiffra, leaving less room for execution hiccups or slower than expected patient access.
The presence of both large upward and downward target revisions in a short window underscores that growth expectations are still being recalibrated, which can add volatility if future data or commentary does not align with the more optimistic scenarios.

Valuation Changes

Fair Value: The $ fair value estimate has risen from $529.00 to $550.00, a modest upward revision.
Discount Rate: The discount rate has fallen slightly from 7.19% to 7.15%.
Revenue Growth: Revenue growth assumptions have been reduced from 42.95% to 35.87%.
Net Profit Margin: The projected net profit margin has risen slightly from 20.33% to 20.71%.
Future P/E: The future P/E multiple has edged higher from 28.61x to 28.75x.

0 views

Key Takeaways

Heavy dependence on a single asset and aggressive market competition threaten both revenue growth and long-term market share.
Expansion into Europe and persistent high expenses are likely to strain margins and hinder profitability due to pricing pressures and limited pipeline diversity.
Strong U.S. sales momentum, patent protection, European expansion, pipeline innovation, and real-world data position Madrigal for substantial long-term revenue and market growth.

Catalysts

About Madrigal Pharmaceuticals

A biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States.What are the underlying business or industry changes driving this perspective?

Accelerating downward pricing pressure from both U.S. and international payers is likely to intensify as government and private insurers scrutinize and negotiate reimbursement for NASH therapies, especially with new alternatives entering the market, leading to lower net revenue per patient and compressing long-term revenue growth.
The expansion into Europe exposes Madrigal to nationalized payer systems that have a history of enforcing significant price concessions and restricting access through strict reimbursement criteria and prior authorization, which will likely prevent the company from achieving the same pricing and margin structure seen in the U.S., directly impacting net margins and future earnings.
Heavy reliance on Rezdiffra as a single asset means future performance is acutely vulnerable to either disappointing long-term outcomes in ongoing trials or faster-than-expected adoption of alternative mechanisms like GLP-1s or next-generation triple agonists, which could erode market share and stall top-line growth.
Long-term demographic risk is intensifying, as population growth in key markets is set to plateau or decline, constraining the available patient pool for chronic MASH therapies and capping addressable market expansion, thereby ultimately limiting sustainable revenue growth beyond initial launch trajectories.
High operating expenses, including surging SG&A and robust ongoing R&D investment without a diversified pipeline, mean that Madrigal may face persistently negative or thin net margins, especially if gross-to-net discounts rise faster than expected or if further capital raises are needed, leading to dilution and weaker earnings per share over time.

Madrigal Pharmaceuticals Earnings and Revenue Growth

Madrigal Pharmaceuticals Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

This narrative explores a more pessimistic perspective on Madrigal Pharmaceuticals compared to the consensus, based on a Fair Value that aligns with the bearish cohort of analysts.
The bearish analysts are assuming Madrigal Pharmaceuticals's revenue will grow by 35.9% annually over the next 3 years.
The bearish analysts assume that profit margins will increase from -27.3% today to 20.7% in 3 years time.
The bearish analysts expect earnings to reach $588.3 million (and earnings per share of $18.85) by about May 2029, up from -$309.4 million today. However, there is some disagreement amongst the analysts with the more bullish ones expecting earnings as high as $1.5 billion.
In order for the above numbers to justify the price target of the more bearish analyst cohort, the company would need to trade at a PE ratio of 29.3x on those 2029 earnings, up from -38.9x today. This future PE is greater than the current PE for the US Biotechs industry at 17.2x.
The bearish analysts expect the number of shares outstanding to grow by 3.44% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 7.15%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

Sustained strong U.S. launch trajectory for Rezdiffra, with annualized net sales exceeding $800 million and rapid quarter-over-quarter growth, signals rising demand and may drive long-term revenue growth.
Newly issued U.S. patent for Rezdiffra offers protection until February 2045, significantly extending the window for exclusive sales and recurring revenue streams, which can support profit expansion and defend net margins for decades.
International expansion beginning with Europe, where Rezdiffra is expected to be the first approved treatment for MASH and is already included as a first-line therapy in guidelines, could substantially expand Madrigal's addressable market and topline.
Pipeline development, including the acquisition of global rights to develop a differentiated oral GLP-1 for combination with Rezdiffra, positions Madrigal to benefit from long-term trends toward combination therapies and supports future multi-asset revenue streams.
Real-world clinical data and ongoing large trials in F4c MASH cirrhosis suggest significant potential to address additional patient segments, including sicker and under-treated populations, potentially doubling the market opportunity and underpinning long-term earnings growth.

Valuation

How have all the factors above been brought together to estimate a fair value?

The assumed bearish price target for Madrigal Pharmaceuticals is $550.0, which represents up to two standard deviations below the consensus price target of $674.36. This valuation is based on what can be assumed as the expectations of Madrigal Pharmaceuticals's future earnings growth, profit margins and other risk factors from analysts on the more bearish end of the spectrum.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $964.0, and the most bearish reporting a price target of just $550.0.
In order for you to agree with the more bearish analyst cohort, you'd need to believe that by 2029, revenues will be $2.8 billion, earnings will come to $588.3 million, and it would be trading on a PE ratio of 29.3x, assuming you use a discount rate of 7.1%.
Given the current share price of $522.23, the analyst price target of $550.0 is 5.0% higher. The relatively low difference between the current share price and the analyst consensus price target indicates that they believe on average, the company is fairly priced.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Madrigal Pharmaceuticals?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystLowTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystLowTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystLowTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

US Pricing Pressure And European Payers Will Erode Margins